Class Level Information	
Class	Levels	Values	
Treatment_group	4	1.Naltrexone + CBI 2.Naltrexone 3.CBI 4.Neither	

Number of Observations Read	721	
Number of Observations Used	721	

Source	DF	Sum of Squares	Mean Square	F Value	Pr > F	
Model	3	6.0253119	2.0084373	3.34	0.0189	
Error	717	431.0806211	0.6012282			
Corrected Total	720	437.1059330				

R-Square	Coeff Var	Root MSE	ldpd Mean	
0.013785	71.38636	0.775389	1.086187	

Source	DF	Type I SS	Mean Square	F Value	Pr > F	
Treatment_group	3	6.02531193	2.00843731	3.34	0.0189	

Source	DF	Type III SS	Mean Square	F Value	Pr > F	
Treatment_group	3	6.02531193	2.00843731	3.34	0.0189	

Treatment_group	ldpd LSMEAN	Standard Error	Pr > |t|	LSMEAN Number	
1.Naltrexone + CBI	1.04179294	0.05929548	<.0001	1	
2.Naltrexone	1.04066247	0.06018186	<.0001	2	
3.CBI	1.00911463	0.05731841	<.0001	3	
4.Neither	1.23172118	0.05469173	<.0001	4	

Least Squares Means for effect Treatment_group
Pr > |t| for H0: LSMean(i)=LSMean(j)

Dependent Variable: ldpd	
i/j	1	2	3	4	
1		0.9893	0.6920	0.0188	
2	0.9893		0.7044	0.0191	
3	0.6920	0.7044		0.0051	
4	0.0188	0.0191	0.0051		

Treatment_group	ldpd LSMEAN	95% Confidence Limits	
1.Naltrexone + CBI	1.041793	0.925379	1.158206	
2.Naltrexone	1.040662	0.922509	1.158816	
3.CBI	1.009115	0.896583	1.121647	
4.Neither	1.231721	1.124346	1.339096	

Least Squares Means for Effect Treatment_group	
i	j	Difference Between Means	95% Confidence Limits for LSMean(i)-LSMean(j)	
1	2	0.001130	-0.164738	0.166999	
1	3	0.032678	-0.129234	0.194590	
1	4	-0.189928	-0.348300	-0.031557	
2	3	0.031548	-0.131620	0.194716	
2	4	-0.191059	-0.350714	-0.031404	
3	4	-0.222607	-0.378147	-0.067066	

Note:	To ensure overall protection level, only probabilities associated with pre-planned comparisons should be used.	

Class Level Information	
Class	Levels	Values	
NALTREXONE	2	0 1	
THERAPY	2	0 1	
ACAMPROSATE	2	0 1	

Number of Observations Read	721	
Number of Observations Used	721	

Source	DF	Sum of Squares	Mean Square	F Value	Pr > F	
Model	7	6.3334835	0.9047834	1.50	0.1648	
Error	713	430.7724495	0.6041689			
Corrected Total	720	437.1059330				

R-Square	Coeff Var	Root MSE	ldpd Mean	
0.014490	71.56073	0.777283	1.086187	

Source	DF	Type I SS	Mean Square	F Value	Pr > F	
ACAMPROSATE	1	0.00374039	0.00374039	0.01	0.9373	
NALTREXONE	1	1.27876310	1.27876310	2.12	0.1462	
NALTREXON*ACAMPROSAT	1	0.19469054	0.19469054	0.32	0.5704	
THERAPY	1	2.51124115	2.51124115	4.16	0.0418	
THERAPY*ACAMPROSATE	1	0.06325160	0.06325160	0.10	0.7464	
NALTREXONE*THERAPY	1	2.27763966	2.27763966	3.77	0.0526	
NALTRE*THERAP*ACAMPR	1	0.00415708	0.00415708	0.01	0.9339	

Source	DF	Type III SS	Mean Square	F Value	Pr > F	
ACAMPROSATE	1	0.00156840	0.00156840	0.00	0.9594	
NALTREXONE	1	1.12312268	1.12312268	1.86	0.1732	
NALTREXON*ACAMPROSAT	1	0.24625741	0.24625741	0.41	0.5234	
THERAPY	1	2.20196009	2.20196009	3.64	0.0567	
THERAPY*ACAMPROSATE	1	0.06358572	0.06358572	0.11	0.7457	
NALTREXONE*THERAPY	1	2.27637873	2.27637873	3.77	0.0526	
NALTRE*THERAP*ACAMPR	1	0.00415708	0.00415708	0.01	0.9339	

NALTREXONE	THERAPY	ACAMPROSATE	ldpd LSMEAN	
0	0	0	1.22667361	
0	0	1	1.23713301	
0	1	0	0.97944017	
0	1	1	1.03721065	
1	0	0	1.06703827	
1	0	1	1.01298416	
1	1	0	1.05487425	
1	1	1	1.02886374	

NALTREXONE	THERAPY	ldpd LSMEAN	Standard Error	Pr > |t|	
0	0	1.23190331	0.05485860	<.0001	
0	1	1.00832541	0.05747987	<.0001	
1	0	1.04001122	0.06034639	<.0001	
1	1	1.04186899	0.05944134	<.0001	

NALTREXONE*THERAPY Effect Sliced by THERAPY for ldpd	
THERAPY	DF	Sum of Squares	Mean Square	F Value	Pr > F	
0	1	3.344843	3.344843	5.54	0.0189	
1	1	0.099426	0.099426	0.16	0.6851	

NALTREXONE*THERAPY Effect Sliced by NALTREXONE for ldpd	
NALTREXONE	DF	Sum of Squares	Mean Square	F Value	Pr > F	
0	1	4.783576	4.783576	7.92	0.0050	
1	1	0.000291	0.000291	0.00	0.9825	

Parameter	Estimate	Standard Error	t Value	Pr > |t|	95% Confidence Limits	
Active vs. placebo naltrexone on CBI	0.03354358	0.08268741	0.41	0.6851	-0.12879635	0.19588351	
Active vs. placebo naltrexone, no CBI	-0.19189209	0.08155460	-2.35	0.0189	-0.35200796	-0.03177623	
CBI vs. no CBI on naltrexone	0.00185778	0.08470513	0.02	0.9825	-0.16444352	0.16815908	
CBI vs. no CBI on placebo naltrexone	-0.22357790	0.07945692	-2.81	0.0050	-0.37957540	-0.06758040	

Model Information	
Data Set	WORK.MONTH4	
Response Variable	ldpd	
Response Distribution	Gaussian	
Link Function	Identity	
Variance Function	Default	
Variance Matrix	Diagonal	
Estimation Technique	Restricted Maximum Likelihood	
Degrees of Freedom Method	Residual	

Class Level Information	
Class	Levels	Values	
NALTREXONE	2	0 1	
THERAPY	2	0 1	
ACAMPROSATE	2	0 1	

Number of Observations Read	721	
Number of Observations Used	721	

Dimensions	
Covariance Parameters	1	
Columns in X	27	
Columns in Z	0	
Subjects (Blocks in V)	1	
Max Obs per Subject	721	

Optimization Information	
Optimization Technique	None	
Parameters	9	
Lower Boundaries	1	
Upper Boundaries	0	
Fixed Effects	Not Profiled	

Fit Statistics	
-2 Res Log Likelihood	1700.11	
AIC  (smaller is better)	1718.11	
AICC (smaller is better)	1718.37	
BIC  (smaller is better)	1759.24	
CAIC (smaller is better)	1768.24	
HQIC (smaller is better)	1733.99	
Pearson Chi-Square	430.77	
Pearson Chi-Square / DF	0.60	

Type III Tests of Fixed Effects	
Effect	Num DF	Den DF	F Value	Pr > F	
ACAMPROSATE	1	713	0.00	0.9594	
NALTREXONE	1	713	1.86	0.1732	
NALTREXON*ACAMPROSAT	1	713	0.41	0.5234	
THERAPY	1	713	3.64	0.0567	
THERAPY*ACAMPROSATE	1	713	0.11	0.7457	
NALTREXONE*THERAPY	1	713	3.77	0.0526	
NALTRE*THERAP*ACAMPR	1	713	0.01	0.9339	

NALTREXONE*THERAPY Least Squares Means	
NALTREXONE	THERAPY	Estimate	Standard Error	DF	t Value	Pr > |t|	
0	0	1.2319	0.05486	713	22.46	<.0001	
0	1	1.0083	0.05748	713	17.54	<.0001	
1	0	1.0400	0.06035	713	17.23	<.0001	
1	1	1.0419	0.05944	713	17.53	<.0001	

NALTREXONE*THERAPY Least Squares Means	
NALTREXONE	THERAPY	Estimate	Standard Error	DF	t Value	Pr > |t|	
0	0	1.2319	0.05486	713	22.46	<.0001	
0	1	1.0083	0.05748	713	17.54	<.0001	
1	0	1.0400	0.06035	713	17.23	<.0001	
1	1	1.0419	0.05944	713	17.53	<.0001	

Class Level Information	
Class	Levels	Values	
NALTREXONE	2	0 1	
THERAPY	2	0 1	
ACAMPROSATE	2	0 1	

Number of Observations Read	721	
Number of Observations Used	721	

Source	DF	Sum of Squares	Mean Square	F Value	Pr > F	
Model	8	37.9985123	4.7498140	8.47	<.0001	
Error	712	399.1074207	0.5605441			
Corrected Total	720	437.1059330				

R-Square	Coeff Var	Root MSE	ldpd Mean	
0.086932	68.92876	0.748695	1.086187	

Source	DF	Type I SS	Mean Square	F Value	Pr > F	
ldpd0	1	29.63970010	29.63970010	52.88	<.0001	
ACAMPROSATE	1	0.07745336	0.07745336	0.14	0.7102	
NALTREXONE	1	0.92673756	0.92673756	1.65	0.1989	
NALTREXON*ACAMPROSAT	1	0.44475197	0.44475197	0.79	0.3734	
THERAPY	1	4.17892122	4.17892122	7.46	0.0065	
THERAPY*ACAMPROSATE	1	0.02856982	0.02856982	0.05	0.8215	
NALTREXONE*THERAPY	1	2.69918247	2.69918247	4.82	0.0285	
NALTRE*THERAP*ACAMPR	1	0.00319577	0.00319577	0.01	0.9398	

Source	DF	Type III SS	Mean Square	F Value	Pr > F	
ldpd0	1	31.66502874	31.66502874	56.49	<.0001	
ACAMPROSATE	1	0.07428354	0.07428354	0.13	0.7159	
NALTREXONE	1	0.76242273	0.76242273	1.36	0.2439	
NALTREXON*ACAMPROSAT	1	0.53709716	0.53709716	0.96	0.3280	
THERAPY	1	3.75467969	3.75467969	6.70	0.0098	
THERAPY*ACAMPROSATE	1	0.03149474	0.03149474	0.06	0.8127	
NALTREXONE*THERAPY	1	2.70028555	2.70028555	4.82	0.0285	
NALTRE*THERAP*ACAMPR	1	0.00319577	0.00319577	0.01	0.9398	

NALTREXONE	THERAPY	ACAMPROSATE	ldpd LSMEAN	
0	0	0	1.23451148	
0	0	1	1.25989725	
0	1	0	0.95742961	
0	1	1	1.00088574	
1	0	0	1.10546676	
1	0	1	1.01280335	
1	1	0	1.06553719	
1	1	1	1.00784150	

NALTREXONE	THERAPY	ldpd LSMEAN	Standard Error	Pr > |t|	
0	0	1.24720437	0.05288013	<.0001	
0	1	0.97915767	0.05550163	<.0001	
1	0	1.05913505	0.05818254	<.0001	
1	1	1.03668935	0.05725926	<.0001	

NALTREXONE*THERAPY Effect Sliced by THERAPY for ldpd	
THERAPY	DF	Sum of Squares	Mean Square	F Value	Pr > F	
0	1	3.212767	3.212767	5.73	0.0169	
1	1	0.292009	0.292009	0.52	0.4707	

NALTREXONE*THERAPY Effect Sliced by NALTREXONE for ldpd	
NALTREXONE	DF	Sum of Squares	Mean Square	F Value	Pr > F	
0	1	6.834837	6.834837	12.19	0.0005	
1	1	0.042357	0.042357	0.08	0.7835	

Parameter	Estimate	Standard Error	t Value	Pr > |t|	95% Confidence Limits	
Active vs. placebo naltrexone on CBI	0.05753167	0.07971013	0.72	0.4707	-0.09896334	0.21402669	
Active vs. placebo naltrexone, no CBI	-0.18806931	0.07855670	-2.39	0.0169	-0.34229980	-0.03383883	
CBI vs. no CBI on naltrexone	-0.02244571	0.08165377	-0.27	0.7835	-0.18275666	0.13786525	
CBI vs. no CBI on placebo naltrexone	-0.26804669	0.07676288	-3.49	0.0005	-0.41875537	-0.11733802